Tacrolimus and sirolimus induce reproductive abnormalities in female rats

Transplantation

Volumn 91, Issue 12, 2011, Pages 1333-1339

  Shivaswamy, Vijay ^a,b,c   Ochsner, Luann ^b   Maroni, Dulce ^b   Wang, Cheng ^b   Passer, Joel ^b   Clure, Cara E ^b   Hamel, Frederick G ^a,b   Davis, John S ^a,b   Larsen, Jennifer ^a,b  

^a VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Corpus luteum; Immunosuppressants; Insulin resistance; Ovary; Polycystic ovary syndrome

Indexed keywords

AROMATASE; GLUCOSE; INSULIN; RAPAMYCIN; TACROLIMUS;

ADULT ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS LUTEUM; ESTRUS CYCLE; FEMALE; GLUCOSE BLOOD LEVEL; GYNECOLOGIC DISEASE; INSULIN RESPONSE; NONHUMAN; ORGAN SIZE; OVARY DISEASE; OVARY FOLLICLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TREATMENT DURATION; UTERUS DISEASE;

ANIMALS; AROMATASE; BLOOD GLUCOSE; ESTRUS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUCOSE; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE AGENTS; INSULIN RESISTANCE; OVARY; PHENOTYPE; POLYCYSTIC OVARY SYNDROME; RATS; RATS, SPRAGUE-DAWLEY; SIROLIMUS; TACROLIMUS; UTERUS;

EID: 79958766333     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31821c1e8b     Document Type: Article

References (36)

1. Davidson J, Wilkinson A, Dantal J, et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 2003: 75(10 suppl): SS3.
2. Hjelmesaeth J, Hartmann A, Leivestad T, et al. The impact of earlydiagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int 2006; 69: 588.
3. Sato T, Inagaki A, Uchida K, et al. Diabetes mellitus after transplant: Relationship to pretransplant glucose metabolism and tacrolimus or cyclosporine A-based therapy. Transplantation 2003; 76: 1320.
4. Sulanc E, Lane JT, Puumala SE, et al. New-onset diabetes after kidney transplantation: An application of 2003 International Guidelines. Transplantation 2005; 80: 945.
5. Penfornis A, Kury-Paulin S. Immunosuppressive drug-induced diabetes. Diabetes Metab 2006; 32(5 pt 2): 539.
6. Larsen JL, Bennett RG, Burkman T, et al. Tacrolimus and sirolimus cause insulin resistance in normal Sprague Dawley rats. Transplantation 2006; 82: 466.
7. Levidiotis V, Chang S, McDonald S. Pregnancy and maternal outcomes among kidney transplant recipients. J Am Soc Nephrol 2009; 20: 2433.
8. Gill JS, Zalunardo N, Rose C, et al. The pregnancy rate and live birth rate in kidney transplant recipients. Am J Transplant 2009; 9: 1541.
9. Mack-Shipman LR, Ratanasuwan T, Leone JP, et al. Reproductive hormones after pancreas transplantation. Transplantation 2000; 70: 1180.
10. Cure P, Pileggi A, Froud T. Alterations of the female reproductive system in recipients of islet grafts. Transplantation 2004; 78: 1576.
11. Alfadhli E, Koh A, Albaker W, et al. High prevalence of ovarian cysts in premenopausal women receiving sirolimus and tacrolimus after clinical islet transplantation. Transpl Int 2009; 22: 622.
12. Vaughan R, Henderson SC, Rahatzad M, et al. Unsuspected adnexal masses in renal transplant recipients. J Urol 1982; 128: 1017.
13. Gaber AO, Kahan BD, Van Buren C, et al. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: Results from an open-label, randomized trial. Transplantation 2008; 86: 1187.
14. Ryan EA, Paty BW, Senior PA, et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005; 54: 2060.
15. Boobes Y, Bernieh B, Saadi H, et al. Gonadal dysfunction and infertility in kidney transplant patients receiving sirolimus. Int Urol Nephrol 2010; 42: 493.
16. Ramos AF, Rodrigues JK, da Silva LR, et al. [Embryo development in rats treated with tacrolimus during the preimplantation phase]. Rev Bras Ginecol Obstet 2008; 30: 219.
17. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41.
18. Woodward RS, Schnitzler MA, Baty J, et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant 2003; 3: 590.
19. Porrini E, Moreno JM, Osuna A, et al. Prediabetes in patients receiving tacrolimus in the first year after kidney transplantation: A prospective and multicenter study. Transplantation 2008; 85: 1133.
20. Johnston O, Rose CL, Webster AC, et al. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008; 19: 1411.
21. Hakeam HA, Al-Jedai AH, Raza SM, et al. Sirolimus induced dyslipidemia in tacrolimus based vs. tacrolimus free immunosuppressive regimens in renal transplant recipients. Ann Transplant 2008; 13: 46.
22. Huyghe E, Zairi A, Nohra J, et al. Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: An overview. Transpl Int 2007; 20: 305.
23. Tondolo V, Citterio F, Panocchia N, et al. Gonadal function and immunosuppressive therapy after renal transplantation. Transplant Proc 2005; 37: 1915.
24. Lee S, Coco M, Greenstein SM, et al. The effect of sirolimus on sex hormone levels of male renal transplant recipients. Clin Transplant 2005; 19: 162.
25. Kayampilly PP, Menon KM. Follicle-stimulating hormone increases tuberin phosphorylation and mammalian target of rapamycin signaling through an extracellular signal-regulated kinase-dependent pathway in rat granulosa cells. Endocrinology 2007; 148: 3950.
26. Alam H, Maizels ET, Park Y, et al. Follicle-stimulating hormone activation of hypoxia-inducible factor-1 by the phosphatidylinositol 3- kinase/AKT/Ras homolog enriched in brain (Rheb)/mammalian target of rapamycin (mTOR) pathway is necessary for induction of select protein markers of follicular differentiation. J Biol Chem 2004; 279: 19431.
27. Hou X, Arvisais EW, Davis JS. Luteinizing hormone stimulates mammalian target of rapamycin signaling in bovine luteal cells via pathways independent of AKT and mitogen-activated protein kinase: Modulation of glycogen synthase kinase 3 and AMP-activated protein kinase. Endocrinology 2010; 151: 2846.
28. Adhikari D, Zheng W, Shen Y, et al. Tsc/mTORC1 signaling in oocytes governs the quiescence and activation of primordial follicles. Hum Mol Genet 2010; 19: 397.
29. Stocco CO, Lau LF, Gibori G. A calcium/calmodulin-dependent activation of ERK1/2 mediates JunD phosphorylation and induction of nur77 and 20alpha-hsd genes by prostaglandin F2alpha in ovarian cells. J Biol Chem 2002; 277: 3293.
30. Stocco CO, Zhong L, Sugimoto Y, et al. Prostaglandin F2alpha-induced expression of 20alpha-hydroxysteroid dehydrogenase involves the transcription factor NUR77. J Biol Chem 2000; 275: 37202.
31. Rusnak F, Mertz P. Calcineurin: Form and function. Physiol Rev 2000; 80: 1483.
32. van Rossum HH, de Fijter JW, van Pelt J. Pharmacodynamic monitoring of calcineurin inhibition therapy: Principles, performance, and perspectives. Ther Drug Monit 2010; 32: 3.
33. Tabata C, Ogita K, Sato K, et al. Calcineurin/NFAT pathway: A novel regulator of parturition. Am J Reprod Immunol 2009; 62: 44.
34. Cattaneo D, Perico N, Remuzzi G. From pharmacokinetics to pharmacogenomics: A new approach to tailor immunosuppressive therapy. Am J Transplant 2004; 4: 299.
35. Hubscher CH, Brooks DL, Johnson JR. A quantitative method for assessing stages of the rat estrous cycle. Biotech Histochem 2005; 80: 79.
36. Volosov A, Napoli KL, Soldin SJ. Simultaneous simple and fast quantification of three major immunosuppressants by liquid chromatography- Tandem mass-spectrometry. Clin Biochem 2001; 34: 285.